1503-98-6

Usage

Uses

Used in Pharmaceutical Industry:
Cyclobutanecarboxamide is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, cyclobutanecarboxamide serves as an intermediate for the production of different agrochemicals, aiding in the creation of products that enhance crop protection and yield.
Used in Polymer Manufacturing:
Cyclobutanecarboxamide is utilized in the manufacturing of polymers, where it plays a role in the formation of polymeric materials with specific properties for various applications.
Used in Organic Synthesis:
As a building block in organic synthesis, cyclobutanecarboxamide is employed in the creation of complex organic molecules for a range of uses, including specialty chemicals and advanced materials.

InChI:InChI=1/C5H9NO/c6-5(7)4-2-1-3-4/h4H,1-3H2,(H2,6,7)

Upstream product

• 75-05-8 acetonitrile 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 3779-29-1 diethyl cyclobutane-1,1-dicarboxylate 
• 5445-51-2 cyclobutane-1,1'-dicarboxylic acid 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 23745-75-7 3-chlorobicyclobutane-1-carbonitrile 

Downstream Products

• 56700-66-4 tert-butyl cyclobutylcarbamate 
• 2516-34-9 cyclobutylamine 
• 156589-97-8 cyclobutancarbothioamide 
• 1620483-46-6 C₃₂H₃₂FN₃O₅ 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 25774-35-0 cyclobutanecarboxylic anhydride 
• 4415-83-2 cyclobutylmethylamine 
• 14924-53-9 ethyl cyclobutylcarboxylate 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 6291-01-6 cyclobutanamine hydrochloride 
• 102520-42-3 cyclobutylamine 4-methylbenzene sulfonate 
• 15907-95-6 N-phenylcyclobutanecarboxamide 
• 4426-11-3 cyclobutanecarbonitrile 
• 3019-25-8 1-cyclobutylethanone 

Relevant academic research and scientific papers

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceuticall acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising th

One-Pot Anodic Conversion of Symmetrical Bisamides of Ethylene Diamine to Unsymmetrical gem-Bisamides of Methylene Diamine

Symmetrical bisamides of ethylene diamine of type ArCONHCH2CH2NHCOAr undergo anodic C-C bond cleavage in acetonitrile-LiClO4 under controlled-potential electrolysis. The electrogenerated carbocation intermediates react with the solvent acetonitrile to afford unsymmetrical gem-bisamides of type ArCONHCH2NHCOMe in a one-pot reaction. The yields of the latter products are moderate (up to 60%). Other minor products involve two symmetrical gem-bisamides of type ArCONHCH2NHCOAr and MeCONHCH2NHCOMe and fragmentation products (e.g., ArCONHCHO, ArCONH2, and ArCN).

Corresponding amine nitrile and method of manufacturing thereof

The invention relates to a manufacturing method of nitrile. Compared with the prior art, the manufacturing method has the characteristics of significantly reduced using amount of an ammonia source, low environmental pressure, low energy consumption, low production cost, high purity and yield of a nitrile product and the like, and nitrile with a more complex structure can be obtained. The invention also relates to a method for manufacturing corresponding amine from nitrile.

SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS

The present invention refers to novel substituted thiazole and oxazole compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties. The compounds are useful in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A′ B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.

METHOD OF USING OPIOID COMPOUNDS AS DELTA OPIOID SELECTIVE AGONIST ANALGESICS

The present invention provides a method for eliminating or ameliorating pain in an animal comprising administrating a therapeutically-effective amount of a substituted morphinoid compound of Formula I: STR1 The compounds are opioid agonists which are useful as analgesic agents for the treatment of pain.

ANALYSE STRUCTURALE EN SERIE CYCLOBUTANIQUE. Partie 1. Derives monosubstitues et gem disubstitues du cyclobutane

Methylene bending mode analysis of some cyclobutane-d2 molecules reveals that in the dissolved state (solvent CCl4), bromocyclobutane occurs exclusively in a pseudo-equatorial form, whereas, under the same conditions, cyclobutanol and 1-bromocyclobutane carbonitrile exist both in pseudo-axial and pseudo-equatorial conformations.NMR spectroscopy confirms the results obtained for bromocyclobutane and leads to the conclusion that the pseudo-equatorial conformer is predominant in the case of cyclobutanol as well as in that of cyclobutane carbonitrile.A theoretical study of cyclobutanol in the gaseous state by the P.C.I.L.O. method gives results which are consistent with a pseudo-equatorial conformer.